172 related articles for article (PubMed ID: 30685272)
1. Deletion of the vesicular monoamine transporter 1 (vmat1/slc18a1) gene affects dopamine signaling.
Lohoff FW; Carr GV; Brookshire B; Ferraro TN; Lucki I
Brain Res; 2019 Jun; 1712():151-157. PubMed ID: 30685272
[TBL] [Abstract][Full Text] [Related]
2. Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture.
Yamamoto H; Kamegaya E; Hagino Y; Imai K; Fujikawa A; Tamura K; Enokiya T; Yamamoto T; Takeshima T; Koga H; Uhl GR; Ikeda K; Sora I
Neurochem Int; 2007; 51(2-4):237-44. PubMed ID: 17664021
[TBL] [Abstract][Full Text] [Related]
3. Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.
Hall FS; Itokawa K; Schmitt A; Moessner R; Sora I; Lesch KP; Uhl GR
Neuropharmacology; 2014 Jan; 76 Pt A(0 0):146-55. PubMed ID: 23978383
[TBL] [Abstract][Full Text] [Related]
4. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.
Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA
J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422
[TBL] [Abstract][Full Text] [Related]
5. Profound changes in dopaminergic neurotransmission in the prefrontal cortex in response to flattening of the diurnal glucocorticoid rhythm: implications for bipolar disorder.
Minton GO; Young AH; McQuade R; Fairchild G; Ingram CD; Gartside SE
Neuropsychopharmacology; 2009 Sep; 34(10):2265-74. PubMed ID: 19494803
[TBL] [Abstract][Full Text] [Related]
6. Selective genetic disruption of dopaminergic, serotonergic and noradrenergic neurotransmission: insights into motor, emotional and addictive behaviour.
Isingrini E; Perret L; Rainer Q; Sagueby S; Moquin L; Gratton A; Giros B
J Psychiatry Neurosci; 2016 Apr; 41(3):169-81. PubMed ID: 26505143
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in the vesicular monoamine transporter 1 (VMAT1/SLC18A1) and neuropsychiatric disorders.
Lohoff FW
Methods Mol Biol; 2010; 637():165-80. PubMed ID: 20419435
[TBL] [Abstract][Full Text] [Related]
8. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Rojas P; Ruiz-Sánchez E; Rojas C; Ogren SO
Neuroscience; 2012 Oct; 223():246-57. PubMed ID: 22885234
[TBL] [Abstract][Full Text] [Related]
9. Differences in the expression of catecholamine-synthesizing enzymes between vesicular monoamine transporter 1- and 2-immunoreactive glomus cells in the rat carotid body.
Kato K; Yokoyama T; Kusakabe T; Hata K; Fushuku S; Nakamuta N; Yamamoto Y
Acta Histochem; 2020 Apr; 122(3):151507. PubMed ID: 31955909
[TBL] [Abstract][Full Text] [Related]
10. Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar i disorder.
Lohoff FW; Dahl JP; Ferraro TN; Arnold SE; Gallinat J; Sander T; Berrettini WH
Neuropsychopharmacology; 2006 Dec; 31(12):2739-47. PubMed ID: 16936705
[TBL] [Abstract][Full Text] [Related]
11. Dopamine transporter and vesicular monoamine transporter knockout mice : implications for Parkinson's disease.
Miller GW; Wang YM; Gainetdinov RR; Caron MG
Methods Mol Med; 2001; 62():179-90. PubMed ID: 21318776
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous composition of dopamine neurons of the rat A10 region: molecular evidence for diverse signaling properties.
Li X; Qi J; Yamaguchi T; Wang HL; Morales M
Brain Struct Funct; 2013 Sep; 218(5):1159-76. PubMed ID: 22926514
[TBL] [Abstract][Full Text] [Related]
13. [Involvement of vesicular monoamine transporter in attention deficit hyperactivity disorder].
Lorenzo-Sanz G; Sánchez-Herranz A
Rev Neurol; 2011 Mar; 52 Suppl 1():S103-8. PubMed ID: 21365590
[TBL] [Abstract][Full Text] [Related]
14. Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice.
Fukushima S; Shen H; Hata H; Ohara A; Ohmi K; Ikeda K; Numachi Y; Kobayashi H; Hall FS; Uhl GR; Sora I
Psychopharmacology (Berl); 2007 Jul; 193(1):55-62. PubMed ID: 17377774
[TBL] [Abstract][Full Text] [Related]
15. VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination.
Multani PK; Hodge R; Estévez MA; Abel T; Kung H; Alter M; Brookshire B; Lucki I; Nall AH; Talbot K; Doyle GA; Lohoff FW
Neuroscience; 2013 Mar; 232():32-44. PubMed ID: 23201251
[TBL] [Abstract][Full Text] [Related]
16. Combined Exposure to Metals in Drinking Water Alters the Dopamine System in Mouse Striatum.
Kim H; Lee D; Kim K
Int J Environ Res Public Health; 2021 Jun; 18(12):. PubMed ID: 34207128
[TBL] [Abstract][Full Text] [Related]
17. Short-term atrazine exposure causes behavioral deficits and disrupts monoaminergic systems in male C57BL/6 mice.
Lin Z; Dodd CA; Filipov NM
Neurotoxicol Teratol; 2013; 39():26-35. PubMed ID: 23770127
[TBL] [Abstract][Full Text] [Related]
18. Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain.
Purves-Tyson TD; Owens SJ; Rothmond DA; Halliday GM; Double KL; Stevens J; McCrossin T; Shannon Weickert C
Transl Psychiatry; 2017 Jan; 7(1):e1003. PubMed ID: 28094812
[TBL] [Abstract][Full Text] [Related]
19. Reduced presynaptic dopamine activity in adolescent dorsal striatum.
Matthews M; Bondi C; Torres G; Moghaddam B
Neuropsychopharmacology; 2013 Jun; 38(7):1344-51. PubMed ID: 23358239
[TBL] [Abstract][Full Text] [Related]
20. Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.
Temple W; Mendelsohn L; Kim GE; Nekritz E; Gustafson WC; Lin L; Giacomini K; Naranjo A; Van Ryn C; Yanik GA; Kreissman SG; Hogarty M; Matthay KK; DuBois SG
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):474-481. PubMed ID: 26338179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
